The neuromuscular disorder spinal muscular atrophy (SMA) is caused by insufficient expression of SMN (survival motor neuron) protein, and the primary goal of SMA therapeutics is to increase SMN levels (Lefebvre et al., 1997). Here, SMN1 is linked to proximal spinal muscular atrophy.